Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275863 | 0.85 | NTRK1 (0.59) | SMN1; SMN2RAB9ANPC1NTRK1CDC7 | |
| SCHEMBL1338860 | 0.85 | TRPM8 (0.49) | SMN1; SMN2KMOPIN1NTRK1LMNA | |
| SCHEMBL1398713 | 0.85 | KMT2A (0.52) | SMN1; SMN2RAB9ANPC1NPSR1KMO | |
| SCHEMBL1398736 | 0.84 | ALDH1A1 (0.52) | SMN1; SMN2RAB9ANPC1PIN1LMNA | |
| SCHEMBL4743844 | 0.82 | ALDH1A1 (0.57) | SMN1; SMN2RAB9ANPC1CDC7DBF4 | |
| SCHEMBL6287392 | 0.82 | F11 (0.52) | PIN1NTRK1 | |
| SCHEMBL1398676 | 0.82 | ALDH1A1 (0.65) | SMN1; SMN2RAB9ANPC1KMOPIN1 | |
| SCHEMBL1398786 | 0.81 | GAA (0.57) | SMN1; SMN2RAB9ANPC1NPSR1NTRK1 | |
| SCHEMBL13494032 | 0.78 | GPR35 (0.54) | SMN1; SMN2KMONTRK1CDC7DBF4 | |
| SCHEMBL8202097 | 0.77 | ALDH1A1 (0.49) | MAPK14SMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| CN-101506199-A | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-12 | — | — | CN | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008087611-A2 | PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | MAPK14 3640/4885SMN1; SMN2 2584/4885RAB9A 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.